Not a good buy right now for an impatient buyer: the trend is decisively bearish (SMA_200 > SMA_20 > SMA_5) and momentum is still deteriorating (MACD histogram negative and expanding).
Even though RSI is extremely oversold (RSI_6 ~19.6) and could spark a short-term bounce, the stock already slipped below the first support (S1 8.257) with the next support near ~7.86—downside can still come quickly.
Options positioning looks aggressively call-leaning, but implied volatility is extremely high (30D IV ~96%), meaning you’re paying up for uncertainty into the next catalyst (earnings 2026-02-26).
Wall Street has been cutting targets and several firms are neutral-to-negative; the most recent notable call (Morgan Stanley) is Underweight with an $8 target—near current price.
Momentum: MACD histogram -0.00572, below zero and negatively expanding → selling pressure is strengthening.
RSI: RSI_6 at 19.597 → deeply oversold; a reflex bounce is possible, but oversold can persist in a downtrend.
Levels: Pivot 8.899 (well above current ~8.16) indicates price is trading below a key balance point.
Support/Resistance: Price is below S1 (8.257); next support S2 ~7.86. Overhead resistance starts near 8.90–9.54.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning/Sentiment: Very call-heavy (OI put/call 0.21; volume put/call 0.15) → traders are leaning bullish/speculative.
Volatility: 30D IV ~96.49 vs historical vol ~46.54 → options are pricing large moves; sentiment may be bullish, but risk/uncertainty is elevated.
IV context: IV percentile ~68.92 (rich vs recent history), while short-term IV averages (5D ~126.9, 10D ~114.9) suggest IV has been elevated and is coming off extremes.
Activity: Today’s volume is small (75 contracts) but open interest is large (total OI ~61,104), implying positioning is built up but today’s flow is not huge.
Technical Summary
Sell
9
Buy
3
Positive Catalysts
can trigger a quick mean-reversion bounce if selling pressure eases.
Neutral/Negative Catalysts
Strongly bearish technical structure (downtrend intact) + weakening momentum (MACD worsening) increases probability of further drawdown before any durable reversal.
Analysts are broadly cutting price targets (multiple reductions in January), highlighting continued uncertainty—especially around the studio business recovery.
Elevated payout/dividend coverage concerns are flagged in sector commentary (Morgan Stanley mentions payout ratio focus).
No supportive near-term news flow (no news in the past week), so the stock may continue to trade purely on weak tape/positioning until earnings.
Earnings risk: with very high implied volatility, disappointment can punish the stock quickly.
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: $186.617M, down 6.87% YoY → top-line pressure persists.
Net income: -$136.467M (still a loss), but improved 39.37% YoY → losses narrowed.
EPS: -2.12, down 56.29% YoY → per-share profitability worsened despite narrower net loss (could reflect share count/one-offs).
Gross margin: still negative (-6.12) but improved materially YoY → cost/asset-level profitability improved, though not yet healthy.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Clear recent trend: price targets have been cut repeatedly from early January through late January 2026, reflecting reduced confidence/expectations.
Latest notable changes:
Morgan Stanley (2026-01-29): Underweight, PT cut to $8 (from $14) → most bearish and near current price.
BMO (2026-01-09): downgraded to Market Perform from Outperform, PT $11.
Pros: potential studio recovery and value realization; some bullish outliers; possible REIT macro tailwinds.
Cons: uncertainty on studio recovery pace, office fundamentals, and multiple PT cuts/downgrades signalling skepticism.
Influential trading check: No recent congress trading data available; insiders show no significant recent trend (neutral).
People Also Watch
Wall Street analysts forecast HPP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HPP is 15.44 USD with a low forecast of 11 USD and a high forecast of 26 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast HPP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HPP is 15.44 USD with a low forecast of 11 USD and a high forecast of 26 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
7 Hold
1 Sell
Hold
Current: 7.850
Low
11
Averages
15.44
High
26
Current: 7.850
Low
11
Averages
15.44
High
26
Morgan Stanley
Ronald Kamdem
Underweight
downgrade
$14 -> $8
AI Analysis
2026-01-29
Reason
Morgan Stanley
Ronald Kamdem
Price Target
$14 -> $8
AI Analysis
2026-01-29
downgrade
Underweight
Reason
Morgan Stanley analyst Ronald Kamdem lowered the firm's price target on Hudson Pacific (HPP) to $8 from $14 and keeps an Underweight rating on the shares. Heading into earnings, the firm looked at office fundamental trends in Q4 in key REIT markets and said it expects elevated payout ratio to be a focus at SL Green Realty (SLG), Highwoods Properties (HIW) and American Assets Trust (AAT).
Goldman Sachs
Neutral
downgrade
2026-01-29
Reason
Goldman Sachs
Price Target
2026-01-29
downgrade
Neutral
Reason
Goldman Sachs lowered the firm's price target on Hudson Pacific to $14.50 from $16.50 and keeps a Neutral rating on the shares.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for HPP
